Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: A meta-analysis

被引:22
作者
ter Veer, Emil [1 ]
Creemers, Aafke [1 ]
de Waal, Laura [1 ]
van Oijen, Martijn G. H. [1 ]
van Laarhoven, Hanneke W. M. [1 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam, Netherlands
关键词
advanced oesophagogastic cancer; HER2; trastuzumab; chemotherapy; meta-analysis; ADVANCED GASTRIC-CANCER; MULTICENTER PHASE-II; S-1 PLUS CISPLATIN; 5-WEEKLY S-1; COMBINATION; CAPECITABINE; OXALIPLATIN; CHEMOTHERAPY; EFFICACY; THERAPY;
D O I
10.1002/ijc.31325
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
According to the Trastuzumab for Gastric Cancer (ToGA) study, trastuzumab plus cisplatin and capecitabine/5-fluorouracil (5-FU) is standard first-line treatment for human epidermal growth factor receptor 2 (HER2)-positive advanced oesophagogastric cancer. We examined the relative efficacy and safety of alternative trastuzumab-based cytotoxic backbone regimens compared to the standard ToGA regimen using meta-analysis. We searched Medline, EMBASE, CENTRAL and ASCO and ESMO up to March 2017 for studies investigating alternative first-line trastuzumab-based regimens for HER2-positive oesophagogastric cancer, defined as high protein expression IHC3+ or IHC2+ and gene amplification by in situ hybridisation. We compared primary outcome overall survival (OS) of alternative trastuzumab-based regimens to the ToGA regimen. Hazard ratios (HRs) and 95% confidence intervals (95% CI) were calculated by extraction of the published Kaplan-Meier curves. Incidence counts and toxicity sample-sizes were extracted for adverse events and compared using single-arm proportion meta-analysis in R. Fifteen studies (N = 557 patients) were included. OS was significantly longer with regimen trastuzumab plus doublet oxaliplatin and capecitabine/5-FU (median OS = 20.7 months) versus ToGA (16.0 months, HR = 0.75, 95% CI = 0.59-0.99) and was less toxic. Trastuzumab plus doublet cisplatin and S-1 showed no OS difference versus ToGA, but showed a different toxicity profile, including less hand-foot syndrome. Trastuzumab plus cisplatin or capecitabine as singlet backbone showed significantly worse survival and more toxicity versus ToGA regimen. Trastuzumab with triplet cytotoxic backbones or with bevacizumab and doublet cytotoxic backbone showed no survival benefit and more toxicity. In conclusion, trastuzumab plus doublet cytotoxic backbone containing oxaliplatin is preferable over the ToGA regimen with cisplatin. S-1 can substitute capecitabine or 5-FU when specific toxicities are encountered.
引用
收藏
页码:438 / 448
页数:11
相关论文
共 35 条
[1]   Gastric Cancer, Version 3.2016 [J].
Ajani, Jaffer A. ;
D'Amico, Thomas A. ;
Almhanna, Khaldoun ;
Bentrem, David J. ;
Chao, Joseph ;
Das, Prajnan ;
Denlinger, Crystal S. ;
Fanta, Paul ;
Farjah, Farhood ;
Fuchs, Charles S. ;
Gerdes, Hans ;
Gibson, Michael ;
Glasgow, Robert E. ;
Hayman, James A. ;
Hochwald, Steven ;
Hofstetter, Wayne L. ;
Ilson, David H. ;
Jaroszewski, Dawn ;
Johung, Kimberly L. ;
Keswani, Rajesh N. ;
Kleinberg, Lawrence R. ;
Korn, W. Michael ;
Leong, Stephen ;
Linn, Catherine ;
Lockhart, A. Craig ;
Ly, Quan P. ;
Mulcahy, Mary F. ;
Orringer, Mark B. ;
Perry, Kyle A. ;
Poultsides, George A. ;
Scott, Walter J. ;
Strong, Vivian E. ;
Washington, Mary Kay ;
Weksler, Benny ;
Willett, Christopher G. ;
Wright, Cameron D. ;
Zelman, Debra ;
McMillian, Nicole ;
Sundar, Hema .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (10) :1286-1312
[2]   Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial [J].
Ajani, Jaffer A. ;
Rodriguez, Wuilbert ;
Bodoky, Gyorgy ;
Moiseyenko, Vladimir ;
Lichinitser, Mikhail ;
Gorbunova, Vera ;
Vynnychenko, Ihor ;
Garin, August ;
Lang, Istvan ;
Falcon, Silvia .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) :1547-1553
[3]   Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin:: A study of the arbeitsgemeinschaft internistische onkologie [J].
Al-Batran, Salah-Eddin ;
Hartmann, Joerg Thomas ;
Probst, Stephan ;
Schmalenberg, Harald ;
Hollerbach, Stephan ;
Hofheinz, Ralf ;
Rethwisch, Volker ;
Seipelt, Gernot ;
Homann, Nils ;
Wilhelm, Gerhard ;
Schuch, Gunter ;
Stoehlmacher, Jan ;
Derigs, Hans Guenter ;
Hegewisch-Becker, Susanna ;
Grossmann, Johannes ;
Pauligk, Claudia ;
Atmaca, Akin ;
Bokemeyer, Carsten ;
Knuth, Alexander ;
Jaeger, Elke .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (09) :1435-1442
[4]  
Bang YJ, 2010, LANCET, V376, P1302
[5]   3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) [J].
Cardoso, F. ;
Costa, A. ;
Senkus, E. ;
Aapro, M. ;
Andre, F. ;
Barrios, C. H. ;
Bergh, J. ;
Bhattacharyya, G. ;
Biganzoli, L. ;
Cardoso, M. J. ;
Carey, L. ;
Corneliussen-James, D. ;
Curigliano, G. ;
Dieras, V. ;
El Saghir, N. ;
Eniu, A. ;
Fallowfield, L. ;
Fenech, D. ;
Francis, P. ;
Gelmon, K. ;
Gennari, A. ;
Harbeck, N. ;
Hudis, C. ;
Kaufman, B. ;
Krop, I. ;
Mayer, M. ;
Meijer, H. ;
Mertz, S. ;
Ohno, S. ;
Pagani, O. ;
Papadopoulos, E. ;
Peccatori, F. ;
Penault-Llorca, F. ;
Piccart, M. J. ;
Pierga, J. Y. ;
Rugo, H. ;
Shockney, L. ;
Sledge, G. ;
Swain, S. ;
Thomssen, C. ;
Tutt, A. ;
Vorobiof, D. ;
Xu, B. ;
Norton, L. ;
Winer, E. .
ANNALS OF ONCOLOGY, 2017, 28 (01) :16-33
[6]   Platinum-Based Versus Non-Platinum-Based Chemotherapy as First Line Treatment of Inoperable, Advanced Gastric Adenocarcinoma: A Meta-Analysis [J].
Chen, Wei-Wei ;
Wang, Feng ;
Xu, Rui-Hua .
PLOS ONE, 2013, 8 (07)
[7]   Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer [J].
Chua, Clarinda ;
Tan, Iain Beehuat ;
Yamada, Yasuhide ;
Rha, Sun Young ;
Yong, Wei Peng ;
Ong, Whee Sze ;
Tham, Chee Kian ;
Ng, Matthew ;
Tai, David W. M. ;
Iwasa, Satoru ;
Lim, Hwee Yong ;
Choo, Su-Pin .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (02) :397-408
[8]   Capecitabine and oxaliplatin for advanced esophagogastric cancer [J].
Cunningham, David ;
Starling, Naureen ;
Rao, Sheela ;
Iveson, Timothy ;
Nicolson, Marianne ;
Coxon, Fareeda ;
Middleton, Gary ;
Daniel, Francis ;
Oates, Jacqueline ;
Norman, Andrew Richard .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (01) :36-46
[9]   Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline [J].
Giordano, Sharon H. ;
Temin, Sarah ;
Kirshner, Jeffrey J. ;
Chandarlapaty, Sarat ;
Crews, Jennie R. ;
Davidson, Nancy E. ;
Esteva, Francisco J. ;
Gonzalez-Angulo, Ana M. ;
Krop, Ian ;
Levinson, Jennifer ;
Lin, Nancy U. ;
Modi, Shanu ;
Patt, Debra A. ;
Perez, Edith A. ;
Perlmutter, Jane ;
Ramakrishna, Naren ;
Winer, Eric P. .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (19) :2078-U148
[10]   Optimal regimen of trastuzumab in combination with oxaliplatin/capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial [J].
Gong, Jifang ;
Liu, Tianshu ;
Fan, Qingxia ;
Bai, Li ;
Bi, Feng ;
Qin, Shukui ;
Wang, Jinwan ;
Xu, Nong ;
Cheng, Ying ;
Bai, Yuxian ;
Liu, Wei ;
Wang, Liwei ;
Shen, Lin .
BMC CANCER, 2016, 16